Study of the therapeutic effect and neutrophil lymphocyte ratio in breast cancer patients who received eribulin

Background: The neutrophil lymphocyte ratio is reported to be a poor prognostic factor in each carcinoma, and the possibility of predicting the therapeutic effect of chemotherapy, for example, is being studied. In this study, we measured the NLR before and after administration of eribulin and the NLR before and after the final administration in breast cancer patients and examined the relationship with the therapeutic effect. Methods: Eleven primary breast cancer patients were examined after eribulin was administered; PD was confirmed eventually, and administration was discontinued. The NLR was determined before the first administration of eribulin and 7 days after the administration; the NLR before the final administration and after the last administration were each tested with p<0.05 as the significance level and using the t test. Results: The average value of NLR before initial administration was 4.07±2.11, and the average value after 7 days of administration was 2.47± 1.97. The NLR before initial administration tended to be higher, and a significant difference was observed (p<0.05). The average NLR value before the final administration was 4.02±2.04, and the average value of the NLR after the final administration was 3.19 ±1.76, showing no significant difference (p=0.27, NS).